A shot in the arm for new antibiotics

Article metrics

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1

IQVIA data from Alan Carr, Needham; FDA; CMS.

References

  1. 1.

    Centers for Medicare and Medicaid Services. FY 2020 IPPS Final Rule, CMS-1716-F (2019); https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2020-IPPS-Final-Rule-Home-Page-Items/FY2020-IPPS-Final-Rule-Regulations.html?DLPage=1&DLEntries=10&DLSort=0&DLSortDir=ascending

  2. 2.

    Verma, S. Aligning payment and prevention to drive antibiotic innovation for Medicare beneficiaries. Health Aff. (Millwood) https://www.healthaffairs.org/do/10.1377/hblog20190802.505113/full/ (2019).

  3. 3.

    Outterson, K. Innovative ways to pay for new antibiotics will help fight superbugs. STAT https://www.statnews.com/2018/04/11/innovation-new-antibiotics-fight-superbugs/ (2018).

  4. 4.

    Wennberg, J. E., McPherson, K. & Caper, P. N. Engl. J. Med. 311, 295–300 (1984).

  5. 5.

    Morrisey, M. A., Sloan, F. A. & Valvona, J. Health Aff. (Millwood) 7, 52–64 (1988).

  6. 6.

    Liu, Z., Dow, W. H. & Norton, E. C. J. Health Econ. 23, 129–155 (2004).

  7. 7.

    Chhabra, K. R., Ibrahim, A. M., Thumma, J. R., Ryan, A. M. & Dimick, J. B. Health Aff. (Millwood) 38, 1207–1215 (2019).

  8. 8.

    Clyde, A. T., Bockstedt, L., Farkas, J. A. & Jackson, C. Health Aff. (Millwood) 27, 1632–1641 (2008).

  9. 9.

    Rex, J. H. et al. Clin. Infect. Dis. 65, 141–146 (2017).

  10. 10.

    Powers, J. H., Evans, S. R. & Kesselheim, A. S. Br. Med. J. 360, k587 (2018).

  11. 11.

    Social Security Act §1886(a)(4) (1989).

  12. 12.

    DISARM Act (2019).

  13. 13.

    Ardal, C.O. et al. Revitalizing the antibiotic pipeline: stimulating innovation while driving sustainable use and global access. DRIVE-AB Final Report (European Commission, Innovative Medicines Initiative, 2018).

  14. 14.

    Outterson, K. et al. PLoS Med. 13, e1002043 (2016).

  15. 15.

    Outterson, K., Powers, J. H., Daniel, G. W. & McClellan, M. B. Health Aff. (Millwood) 34, 277–285 (2015).

  16. 16.

    Outterson, K. Cardozo Law Rev. 31, 613 (2010).

  17. 17.

    Kesselheim, A. S. & Outterson, K. Yale J. Health Policy Law Ethics 11, 101–167 (2011).

  18. 18.

    O’Neill, J. Tackling drug-resistant infections globally: final report and recommendations (Review on Antimicrobial Resistance, London, 2016).

  19. 19.

    Clift, C. et al. Towards a new global business model for antibiotics: report from the Chatham House Working Group on New Antibiotic Business Models (London, 2015).

Download references

Author information

Correspondence to Kevin Outterson.

Ethics declarations

Competing interests

K.O. is the executive director of CARB-X, funded by three governments (US, UK and Germany) and two foundations (Wellcome Trust and Gates). CARB-X is a non-profit accelerator of preclinical and phase 1 antibacterial research that awards grants worldwide.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Outterson, K. A shot in the arm for new antibiotics. Nat Biotechnol 37, 1110–1112 (2019) doi:10.1038/s41587-019-0279-8

Download citation